Company Overview and News

 
Check out insider trades for August 31; IDFC Bank, Liberty Shoes, HDFC in focus

2018-09-03 moneycontrol
Camlin Fine Sciences.: Ashish Subhash Dandekar (promoter) bought 1,38,10,550 shares through market purchase on August 30 and August 31, 2018
LIBERTSHOE PANAMAPET 533260 533298 HDFC 532834 539437 IDFCBANK CAREERP SURANASOL 526596 524820 CAMLINFIN 500010 HDFC

 
Liberty Shoes rises 5% as Q1 profit more than doubles to Rs 2.26 crore

2018-08-10 moneycontrol
Shares of Liberty Shoes rose 5 percent on Friday morning as investors cheered its financial results for the June quarter.
LIBERTSHOE 526596

 
Footwear, paint, consumer durables, FMCG stocks surge up to 10% on GST rate cut

2018-07-23 freepressjournal.in
New Delhi: Shares of footwear, paint makers, consumer durables and FMCG companies surged up to 10 per cent today after the GST Council reduced tax rates on a number of products.
LIBERTSHOE 517421 500820 SHALPAINTS 530517 KAJARIACER HINDUNILVR 532953 ASIANPAINT MIRZAINT RELAXO VGUARD 500233 500696 526642 500031 517354 500710 HVLQY 505726 KNZAY BATAINDIA KANSAINER AKZOINDIA HAVELLS IFBIND BUTTERFLY 526596 500043 509874 BAJAJELEC 500165

 
Footwear, paint, consumer durables, FMCG stocks surge up to 10% on GST rate cut

2018-07-23 thehindubusinessline
Shares of footwear, paint makers, consumer durables and FMCG companies surged up to 10 per cent today after the GST Council reduced tax rates on a number of products.
LIBERTSHOE 517421 500820 SHALPAINTS 530517 KAJARIACER 532953 ASIANPAINT MIRZAINT RELAXO VGUARD 500233 526642 500031 517354 500710 HVLQY 505726 KNZAY BATAINDIA KANSAINER AKZOINDIA HAVELLS IFBIND BUTTERFLY 526596 500043 509874 BAJAJELEC 500165

21
Market Live: Sell-off continues on trade tensions; all sectoral indices in the red

2018-06-19 moneycontrol
Oil Prices Update: Oil prices fell nearly one percent as an escalating trade dispute between the United States and China triggered sharp selloffs in many global markets.
LIBERTSHOE 523768 500325 GOACARBON GUJBOROS RELIANCE GLKQY 539437 500470 IDFCBANK RIGD 500790 NSZTY RLNIY 509567 SBAZ GLENMARK IBN 502219 TATAPOWER NESTLEIND HEXAWARE 539302 532129 POWERMECH BOROSIL ICICIBANK TTST 532296 TATASTEEL TATLY 532174 TPCL 500400 526596

36
Market Live: Sensex extends losses amid trade war woes; IOC, HPCL, BPCL dip 3%

2018-06-19 moneycontrol
Glenmark Pharmaceuticals announced that the US Food & Drug Administration provided its first supplemental abbreviated new drug application (sANDA) approval for the company’s manufacturing facility in Monroe, North Carolina.
LIBERTSHOE 523768 500325 GUJBOROS RELIANCE KAJARIACER 532418 BHRQY GLKQY 532215 JUSTDIAL CMQMY 500470 535648 533407 AXISBANK RIGD 500233 CUMMINSIND BHARTIARTL 500790 NSZTY RLNIY SBAZ GLENMARK AXB 502219 IBN NESTLEIND HEXAWARE 539302 532129 AXBKY POWERMECH 532454 BOROSIL AXBA 500480 ICICIBANK TTST 532296 TATASTEEL TATLY 532174 CNOVAPETRO 526596 JSTQY ANDHRABANK

2
Liberty Shoes Limited - Clarification - Financial Results

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
LIBERTSHOE 526596

2
Liberty Shoes Limited - News Clarification

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
LIBERTSHOE 526596

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...